These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19960891)

  • 1. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
    Glueck CJ; Goldenberg N; Wang P
    J Pediatr Endocrinol Metab; 2009 Sep; 22(9):815-26. PubMed ID: 19960891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
    Glueck CJ; Aregawi D; Winiarska M; Agloria M; Luo G; Sieve L; Wang P
    J Pediatr Endocrinol Metab; 2006 Jun; 19(6):831-42. PubMed ID: 16886591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.
    Glueck CJ; Wang P; Fontaine R; Tracy T; Sieve-Smith L
    Metabolism; 1999 Apr; 48(4):511-9. PubMed ID: 10206447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).
    Glueck CJ; Wang P; Fontaine R; Tracy T; Sieve-Smith L
    J Adolesc Health; 2001 Sep; 29(3):160-9. PubMed ID: 11524214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
    Glueck CJ; Moreira A; Goldenberg N; Sieve L; Wang P
    Hum Reprod; 2003 Aug; 18(8):1618-25. PubMed ID: 12871871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome.
    Yang PK; Hsu CY; Chen MJ; Lai MY; Li ZR; Chen CH; Chen SU; Ho HN
    J Clin Endocrinol Metab; 2018 Mar; 103(3):890-899. PubMed ID: 29325133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance.
    Goldenberg N; Glueck CJ; Loftspring M; Sherman A; Wang P
    Metabolism; 2005 Jan; 54(1):113-21. PubMed ID: 15562389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
    Morin-Papunen LC; Koivunen RM; Ruokonen A; Martikainen HK
    Fertil Steril; 1998 Apr; 69(4):691-6. PubMed ID: 9548159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
    Gambineri A; Pelusi C; Genghini S; Morselli-Labate AM; Cacciari M; Pagotto U; Pasquali R
    Clin Endocrinol (Oxf); 2004 Feb; 60(2):241-9. PubMed ID: 14725687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy.
    Glueck CJ; Goldenberg N; Wang P; Loftspring M; Sherman A
    Hum Reprod; 2004 Mar; 19(3):510-21. PubMed ID: 14998944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.
    Glueck CJ; Papanna R; Wang P; Goldenberg N; Sieve-Smith L
    Metabolism; 2003 Jul; 52(7):908-15. PubMed ID: 12870169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
    Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH
    Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
    Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.
    Yasmin E; Glanville J; Barth J; Balen AH
    Eur J Obstet Gynecol Reprod Biol; 2011 May; 156(1):67-71. PubMed ID: 21277073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
    Glueck CJ; Aregawi D; Agloria M; Winiarska M; Sieve L; Wang P
    Metabolism; 2006 Dec; 55(12):1582-9. PubMed ID: 17142128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.